scholarly journals Mismatched Donor Lymphocyte Infusions for Relapsed Acute Leukemia Following HLA Identical Allogeneic Stem Cell Transplant

2011 ◽  
Vol 17 (2) ◽  
pp. S215
Author(s):  
Z.A. McIver ◽  
M. Battiwalla ◽  
A.J. Barrett
Keyword(s):  
Stem Cell ◽  
Acute Leukemia ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
Mismatched Donor ◽  
Donor Lymphocyte Infusions

scholarly journals A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Claire Horgan ◽  
Alexandros Kanellopoulos ◽  
Shankara Paneesha ◽  
Bhuvan Kishore ◽  
Richard Lovell ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Myeloid Leukemia ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
Unique Case ◽  
Reduced Intensity ◽  
Acute Myeloid ◽  
Donor Lymphocyte Infusions

A unique case of primary refractory FLT3-itd mutated acute myeloid leukemia in an elderly patient, who achieved completed morphological remission, and FLT3-itd negativity, following 9 cycles of azacitadine in combination with escalating doses of donor lymphocyte infusions following relapse 18 months post reduced intensity HLAA mismatch Campath conditioning allogeneic stem cell transplant.

scholarly journals Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Heather Klocke ◽  
Zhao Ming Dong ◽  
Craig O’Brien ◽  
Nicholas Burwick ◽  
Robert E. Richard ◽  
...  
Keyword(s):  
Stem Cell ◽  
Acute Leukemia ◽  
Stem Cell Transplant ◽  
Treatment Guidelines ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
Not Otherwise Specified ◽  
Mixed Phenotype Acute Leukemia ◽  
One Year ◽  
Mixed Phenotype

T/myeloid mixed-phenotype acute leukemia not otherwise specified (MPAL NOS) is an uncommon and aggressive leukemia without well-established treatment guidelines, particularly when relapsed. Venetoclax plus a hypomethylating agent offers a promising option in this situation since studies support its use in both acute myeloid and, albeit with fewer data to date, acute T-cell-lymphoblastic leukemias. We report the successful eradication of T/myeloid MPAL NOS relapsed after allogeneic stem cell transplant with venetoclax plus decitabine. A consolidative allogeneic stem cell transplant from a second donor was subsequently performed, and the patient remained without evidence of disease more than one year later. Further investigation is indicated to evaluate venetoclax combined with hypomethylating agents and/or other therapies for the management of T/myeloid MPAL NOS.

Prognostic index for relapsed acute leukemia after allogeneic stem cell transplant

2014 ◽  
Vol 55 (12) ◽  
pp. 2808-2812 ◽  
Author(s):  
Kenji Matsumoto ◽  
Wataru Yamamoto ◽  
Eriko Ogusa ◽  
Yoshiaki Ishigatsubo ◽  
Heiwa Kanamori
Keyword(s):  
Stem Cell ◽  
Acute Leukemia ◽  
Stem Cell Transplant ◽  
Prognostic Index ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant
Sign in / Sign up

Export Citation Format

Share Document